Inventor

DAVIS ROBERT

US166 patents

⚠️ This page may combine multiple inventors who share the name “DAVIS ROBERT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

DAVIS ROBERT

INTRA CELLULAR THERAPIES INC

Substituted pyrido[3&#39;,4&#39;:4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity

Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders

Compositions and methods

Methods

Methods of treating bipolar disorder

Methods of treating schizophrenia and depression

Pharmaceutical compositions for sustained or delayed release

Organic compounds

Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system

Transmucosal and subcutaneous compositions

Organic compounds

Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3&#39;,4&#39;:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl) butan-1-one for inhibiting serotonin reuptake transporter activity

Methods

Organic compounds

Organic compounds

Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity

Method for the treatment of residual symptoms of schizophrenia

Organic compounds

Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders

Pharmaceutical capsules comprising lumateperone mono-tosylate

Pharmaceutical capsule compositions comprising lumateperone mono-tosylate

Transmucosal methods for treating psychiatric and neurological conditions

Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate

Pharmaceutical compositions comprising 4-(6Br,10aS)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1H, 7H-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8YL)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system

Organic compounds

Methods of treating acute depression and/or acute anxiety

Compounds and methods

Pharmaceutical capsule compositions comprising lumateperone mono-tosylate

Organic compounds

Organic compounds

Pharmaceutical capsule compositions comprising lumateperone mono-tosylate

Transmucosal methods for treating psychiatric and neurological conditions

Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders

Organic compounds

Organic compounds

Pharmaceutical capsule compositions comprising lumateperone mono-tosylate

SORTEX LTD

Sorting apparatus

Sorting apparatus

Sorting apparatus

Sorting apparatus

NUVERA FUEL CELLS INC

Integrated hydrocarbon reforming system and controls

Auxiliary reactor for a hydrocarbon reforming system

LINVATEC CORP

Surgical reamer

MATES SHARON

Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives

CAPE ANALYTICS INC

Method and system for automated debris detection

DIRECTTV GROUP INC

Multi-processor DVR

(unassigned)

Method of loading product into a contained bag

DAVIS ROBERT

Inflatable laptop desk

INTEGRATED MATERIALS INC

Method and apparatus for fabricating elongate crystalline members

SCHLOEMANN SIEMAG AG

Method and plant for rolling hot-rolled wide strip in a CSP plant

Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity

Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl) butan-1-one for inhibiting serotonin reuptake transporter activity